Healthcare provider profile · identity verified

Lu You, MD

Allopathic & Osteopathic Physicians|General Practice · NEW YORK, NY · NPI 1518258003

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Lu You, MD received $360.41 in general payments during 2025 across 13 reported records.

Gilead Sciences, Inc. accounted for 94.8% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Farxiga by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Nexium by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.

Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Vemlidy by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$360.41

13 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Gilead Sciences, Inc.	Unresolved — no canonical attribution shown	$341.49	94.8%	12	2025
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$18.92	5.2%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$360.41	13

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
FARXIGA Normalized: farxiga	Drug	AstraZeneca Pharmaceuticals LP	$18.92	1	2025
Source payment records 2025-12-04 · AstraZeneca Pharmaceuticals LP · $18.92 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
FARXIGA farxiga	2025	Farxiga	2024	133	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	133	43
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	NEXIUM open payments reported associated product	CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180	Nexium · 2024 Exact normalized brand match · 1 Part D row	26	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	SYMBICORT open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610	Symbicort · 2024 Exact normalized brand match · 1 Part D row	24	suppressed by CMS
Gilead Sciences, Inc. Exact reporting entity; no affiliate inference	2025	Vemlidy open payments reported associated product	CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906	Vemlidy · 2024 Exact normalized brand match · 1 Part D row	63	12

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1417	489
Amlodipine Besylate	Amlodipine Besylate	807	259
Losartan Potassium	Losartan Potassium	727	251
Metformin Hcl	Metformin Hcl	347	111
Vascepa	Icosapent Ethyl	343	94
Tamsulosin Hcl	Tamsulosin Hcl	326	102
Metoprolol Succinate	Metoprolol Succinate	305	114
Levothyroxine Sodium	Levothyroxine Sodium	274	79
Ammonium Lactate	Ammonium Lactate	253	80
Olmesartan Medoxomil	Olmesartan Medoxomil	248	66
Omeprazole	Omeprazole	247	109
Shingrix	Varicella-Zoster Ge/As01b/Pf	199	137
Rosuvastatin Calcium	Rosuvastatin Calcium	179	71
Meclizine Hcl	Meclizine Hcl	176	96
Raloxifene Hcl	Raloxifene Hcl	169	56
Jardiance	Empagliflozin	168	38
Triamcinolone Acetonide	Triamcinolone Acetonide	160	96
Albuterol Sulfate Hfa	Albuterol Sulfate	154	56
Montelukast Sodium	Montelukast Sodium	152	42
Alendronate Sodium	Alendronate Sodium	140	56
Fluticasone Propionate	Fluticasone Propionate	137	59
Farxiga	Dapagliflozin Propanediol	133	43
Finasteride	Finasteride	131	47
Simvastatin	Simvastatin	122	37
Lisinopril	Lisinopril	116	30
Atenolol	Atenolol	108	31
Januvia	Sitagliptin Phosphate	107	36
Azelastine Hcl	Azelastine Hcl	101	44
Diclofenac Sodium	Diclofenac Sodium	93	47
Donepezil Hcl	Donepezil Hcl	88	39
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	83	28
Tradjenta	Linagliptin	83	18
Famotidine	Famotidine	81	41
Allopurinol	Allopurinol	75	24
Clopidogrel	Clopidogrel Bisulfate	71	26
Hydrocortisone	Hydrocortisone	71	26
Glimepiride	Glimepiride	70	22
Naproxen	Naproxen	67	54
Chlorhexidine Gluconate	Chlorhexidine Gluconate	66	21
Esomeprazole Magnesium	Esomeprazole Magnesium	65	22
Vemlidy	Tenofovir Alafenamide	63	12
Gabapentin	Gabapentin	60	25
Prolia	Denosumab	59	46
Mometasone Furoate	Mometasone Furoate	58	25
Metoprolol Tartrate	Metoprolol Tartrate	53	18
Hydrochlorothiazide	Hydrochlorothiazide	52	21
Pioglitazone Hcl	Pioglitazone Hcl	51	17
Nebivolol Hcl	Nebivolol Hcl	50	15
Glipizide Er	Glipizide	48	17
Hydralazine Hcl	Hydralazine Hcl	48	17
Nifedipine Er	Nifedipine	48	12
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	47	17
Folic Acid	Folic Acid	46	15
Rybelsus	Semaglutide	46	15
Alcohol Prep Pads	Alcohol Antiseptic Pads	45	23
Eliquis	Apixaban	45	14
Procto-Med Hc	Hydrocortisone	45	17
Pantoprazole Sodium	Pantoprazole Sodium	43	15
Glipizide-Metformin	Glipizide/Metformin Hcl	42	17
Mupirocin	Mupirocin	42	34
Ibuprofen	Ibuprofen	40	38
Diclofenac Epolamine	Diclofenac Epolamine	39	27
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	39	15
Isosorbide Mononitrate Er	Isosorbide Mononitrate	37	13
Clobetasol Propionate	Clobetasol Propionate	34	26
Halobetasol Propionate	Halobetasol Propionate	34	28
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	31	28
Azithromycin	Azithromycin	30	28
Glipizide	Glipizide	30	suppressed
Tenofovir Disoproxil Fumarate	Tenofovir Disoproxil Fumarate	30	suppressed
Restasis	Cyclosporine	29	suppressed
Xarelto	Rivaroxaban	28	suppressed
Colchicine	Colchicine	27	suppressed
Loperamide	Loperamide Hcl	27	26
Fenofibrate	Fenofibrate,micronized	26	suppressed
Nexium	Esomeprazole Magnesium	26	suppressed
Ranolazine Er	Ranolazine	25	suppressed
Trazodone Hcl	Trazodone Hcl	25	13
Zolpidem Tartrate	Zolpidem Tartrate	25	16
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	24	13
Prednisone	Prednisone	24	20
Symbicort	Budesonide/Formoterol Fumarate	24	suppressed
Icosapent Ethyl	Icosapent Ethyl	23	suppressed
Meloxicam	Meloxicam	23	13
Single Use Swab	Alcohol Antiseptic Pads	23	suppressed
Acarbose	Acarbose	22	suppressed
Dutasteride	Dutasteride	22	suppressed
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	22	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	22	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	22	suppressed
Calcitriol	Calcitriol	21	suppressed
Bepotastine Besilate	Bepotastine Besilate	20	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	20	suppressed
Incruse Ellipta	Umeclidinium Bromide	20	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	20	suppressed
Carvedilol	Carvedilol	19	suppressed
Clotrimazole	Clotrimazole	19	14
Dexlansoprazole Dr	Dexlansoprazole	19	suppressed
Furosemide	Furosemide	19	13
Irbesartan	Irbesartan	19	suppressed
Nitroglycerin	Nitroglycerin	18	suppressed
Silodosin	Silodosin	18	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	17	16
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	16	suppressed
Repatha Sureclick	Evolocumab	16	suppressed
Spironolactone	Spironolactone	16	suppressed
Telmisartan	Telmisartan	16	suppressed
Ventolin Hfa	Albuterol Sulfate	16	suppressed
Celecoxib	Celecoxib	15	suppressed
Ketoconazole	Ketoconazole	15	suppressed
Ursodiol	Ursodiol	15	suppressed
Ezetimibe	Ezetimibe	14	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	13	suppressed
Potassium Citrate Er	Potassium Citrate	13	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	12	12
Levofloxacin	Levofloxacin	12	12
Torsemide	Torsemide	12	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	11	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	11	suppressed
Bydureon Bcise	Exenatide Microspheres	11	suppressed
Cephalexin	Cephalexin	11	suppressed
Ciclopirox	Ciclopirox	11	suppressed
Creon	Lipase/Protease/Amylase	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Lidocaine	Lidocaine	11	suppressed
Livalo	Pitavastatin Calcium	11	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	11	11
Pregabalin	Pregabalin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$360.41 · 13 records	Gilead Sciences, Inc.	FARXIGA	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Farxiga play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error